Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Fort Worth, Texas 76134


Purpose:

A multi-center, double-masked, randomized parallel group efficacy and safety study of brinzolamide 1% /brimonidine 0.2% fixed combination compared to brinzolamide 1% plus brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.


Criteria:

Inclusion Criteria: - Patients 18 years of age or older, of either gender, and any race/ethnicity, diagnosed with open-angle glaucoma or ocular hypertension who in the opinion of the Investigator are insufficiently controlled on monotherapy or are currently on multiple IOP-lowering medications. - Patients meeting qualifying IOP entry criteria. - Able to understand and sign an informed consent form that has been approved by an Institutional Review Board/Independent Ethics Committee. Exclusion Criteria: - Schaffer angle Grade < 2 - Cup/disc ratio greater than 0.80 - Severe central visual field loss - Best Corrected VA score worse than 55 ETDRS letters (20/80 Snellen equivalent) - Chronic, recurrent or severe inflammatory eye disease - Clinically significant or progressive retinal disease - Other ocular pathology - Patients with recent use of high-dose (>1 gm daily) salicylate therapy - Recent, current, or anticipated treatment with any medication that augments adrenergic responses, or precludes use of an alpha-adrenergic agonist


NCT ID:

NCT01309204


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Fort Worth, Texas 76134
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.